Table 1.

Demographic and clinical characteristics of 1555 patients in the study cohort

Patient Clinical CharacteristicsAllNormal: eGFR≥90Mildly Impaired: eGFR≥60 to <90Moderately Impaired: eGFR≥30 to <60Severely Impaired: eGFR<30On DialysisP Value
N15557224452298178
Age, mean (SD)58 (15)52 (14)61 (14)68 (15)63 (13)58 (13)<0.001
MI at presentation, high sensitivity, n (%)167 (11)49 (7)50 (11)41 (18)17 (21)10 (13)<0.001
MI at presentation, contemporary, n (%)205 (13)72 (10)61 (14)46 (20)14 (17)12 (15)0.001
Sex, n (%)<0.001
 Men881 (57)455 (63)236 (53)104 (45)43 (53)43 (55)
 Women674 (43)267 (37)209 (47)125 (55)38 (47)35 (45)
Race, n (%)<0.001
 White669 (43)278 (39)235 (53)113 (49)29 (36)14 (18)
 Black668 (43)332 (46)166 (37)86 (38)37 (46)47 (60)
 Native American84 (5)48 (7)13 (3)10 (4)8 (10)5 (6)
 Asian46 (3)19 (3)11 (2)8 (3)5 (6)3 (4)
 Other88 (6)45 (6)20 (4)12 (5)2 (2)9 (12)
Medical history, n (%)
 Hypertension1032 (66)406 (56)297 (67)189 (83)70 (86)70 (90)<0.001
 Diabetes486 (31)201 (28)117 (26)86 (38)47 (58)35 (45)<0.001
 Current smoker567 (36)322 (45)150 (34)54 (24)17 (21)24 (31)<0.001
 Dyslipidemia670 (43)245 (34)205 (46)137 (60)49 (60)34 (44)<0.001
 Drug use205 (13)105 (15)54 (12)25 (11)6 (7)15 (19)0.11
 Previous acute MI184 (12)72 (10)49 (11)41 (18)12 (15)10 (13)0.02
 Coronary artery disease259 (17)85 (12)79 (18)59 (26)22 (27)14 (18)<0.001
 Previous cardiac arrest20 (1)5 (1)7 (2)6 (3)0 (0)2 (3)0.11
 Previous PCI or stent153 (10)55 (8)47 (11)38 (17)9 (11)4 (5)0.001
 Heart failure224 (14)56 (8)58 (13)62 (27)25 (31)23 (29)<0.001
 Atrial fibrillation126 (8)31 (4)42 (9)34 (15)10 (12)9 (12)<0.001
 Previous CABG72 (5)26 (4)17 (4)17 (7)7 (9)5 (6)0.04
 Peripheral vascular disease41 (3)11 (2)16 (4)8 (3)5 (6)1 (1)0.04
 Previous stroke147 (9)42 (6)53 (12)33 (14)10 (12)9 (12)<0.001
 Pace maker86 (6)20 (3)27 (6)27 (12)7 (9)5 (6)<0.001
 Body mass index30 (9)30 (10)30 (8)29 (9)31 (10)28 (10)0.10
Symptoms, n (%)
 Chest discomfort442 (28)256 (35)120 (27)35 (15)16 (20)15 (19)<0.001
 Arm or shoulder discomfort226 (15)128 (18)71 (16)16 (7)6 (7)5 (6)<0.001
 Jaw or neck discomfort92 (6)47 (7)27 (6)12 (5)4 (5)2 (3)0.67
 Epigastric discomfort87 (6)50 (7)19 (4)9 (4)5 (6)4 (5)0.27
 Nausea or vomiting365 (23)195 (27)93 (21)44 (19)21 (26)12 (15)0.02
 Dyspnea644 (41)295 (41)183 (41)94 (41)34 (42)38 (49)0.76
 Fatigue77 (5)26 (4)18 (4)21 (9)7 (9)5 (6)<0.01
 Diaphoresis156 (10)89 (12)45 (10)17 (7)3 (4)2 (3)<0.01
Laboratory values, mean (SD)
 NT-proBNP, ng/L3064 (7213)955 (1775)1533 (2416)4247 (8979)9679 (13,170)18,303 (13,707)<0.001
 eGFR, ml/min per 1.73 m285 (41)119 (28)76 (8)47 (8)17 (7)10 (13)<0.001
 Hemoglobin, g/dl13 (2)13 (2)13 (2)12 (2)11 (3)10 (2)<0.001
 Baseline hs-cTnI, ng/L79 (1169)96 (1642)41 (204)61 (346)209 (1263)62 (166)0.79
 Maximum hs-cTnI, ng/L368 (2933)359 (3299)198 (1266)621 (3858)833 (3980)196 (1149)0.24
 Baseline contemporary cTnI, μg/L0.09 (1.29)0.11 (1.82)0.05 (0.23)0.07 (0.28)0.26 (1.49)0.07 (0.15)0.73
 Maximum contemporary cTnI, μg/L0.42 (3.60)0.45 (4.17)0.19 (1.01)0.73 (5.10)0.80 (3.56)0.18 (0.91)0.30
  • Normal: eGFR≥90 ml/min per 1.73 m2; mildly impaired: eGFR≥60 to <90 ml/min per 1.73 m2; moderately impaired: eGFR≥30 to <60 ml/min per 1.73 m2; severely impaired: eGFR≤30 ml/min per 1.73 m2. PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; NT-proBNP, N-terminal pro B-type natiuretic peptide.